Tarsus Pharmaceuticals, Inc. TARS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $162.05M+107% | $151.67M+128% | $118.7M+147% | $102.66M+152% | $78.34M+184% | ||
| $9.4M+80.3% | —— | —— | —— | $5.21M— | ||
| $152.66M+109% | —— | —— | —— | $73.12M— | ||
| 94.2%+0.9pp | —— | —— | —— | 93.3%— | ||
| $22.35M+55.1% | $18.04M+6.9% | $16.28M+34.3% | $15.59M+26.6% | $14.41M+19.4% | ||
| $136.43M+60.5% | $130.68M+89.3% | $108.63M+87.6% | $103.01M+75.2% | $85M+64.8% | ||
| $168.18M+60.8% | $159.64M+75.8% | $133.23M+81.8% | $124.84M+68.4% | $104.62M+60.2% | ||
| -$6.12M+76.7% | -$7.98M+67.3% | -$14.53M+42.3% | -$22.18M+33.4% | -$26.28M+30.3% | ||
| -3.8%+29.8pp | -5.3%+31.5pp | -12.2%+40.1pp | -21.6%+60.0pp | -33.5%+103pp | ||
| $2.13M-3.8% | $2.21M-4.2% | $2.27M-7.2% | $2.24M+6.2% | $2.21M+125% | ||
| $3.72M+7.8% | $3.95M+8.3% | $4.11M-0.1% | $4.23M+2.4% | $3.45M+10.8% | ||
| $1.51M+29.9% | $1.66M+27.1% | $1.94M+11.6% | $1.84M+15,267% | $1.16M-40.6% | ||
| —— | -$16.09M+44.3% | -$16.09M+44.3% | -$16.09M+44.3% | -$16.09M+44.3% | ||
| $2.35M— | —— | —— | —— | $0— | ||
| -$6.97M+72.3% | -$8.37M+63.8% | -$12.59M+46.3% | -$20.34M+38.9% | -$25.12M+29.7% | ||
| -4.3%+27.8pp | -5.5%+29.3pp | -10.6%+38.1pp | -19.8%+61.8pp | -32.1%+97.3pp | ||
| -$0.16+75.0% | -$0.19+67.8% | -$0.30+50.8% | -$0.48+45.5% | -$0.64+36.6% | ||
| -$0.16+75.0% | -$0.19+67.8% | -$0.30+50.8% | -$0.48+45.5% | -$0.64+36.6% | ||
| 43M+9.2% | 41.8M+11.1% | 42.6M+11.0% | 42.4M+12.0% | 39.3M+11.5% | ||
| 43M+9.2% | 41.8M+11.1% | 42.6M+11.0% | 42.4M+12.0% | 39.3M+11.5% | ||
| -$7.65M+69.7% | -$8.28M+64.4% | -$12.34M+46.1% | -$20.39M+39.0% | -$25.21M+29.6% | ||
| $3.72M+7.8% | $3.95M+8.3% | $4.11M-0.1% | $4.23M+2.4% | $3.45M+10.8% | ||
| -$679K-622% | $92K— | $250K-52.1% | -$46K+59.3% | -$94K-54.1% | ||
| -$87K-7.4% | -$74K-174% | $98K+46.3% | -$145K-123% | -$81K+55.2% | ||
| -$6.12M+76.7% | -$7.98M+67.3% | -$14.53M+42.3% | -$22.18M+33.4% | -$26.28M+30.3% | ||
| -$5.69M+78.0% | -$7.53M+68.6% | -$14.13M+43.2% | -$21.78M+34.2% | -$25.82M+31.0% | ||
| -$5.69M+78.0% | -$7.53M+68.6% | -$14.13M+43.2% | -$21.78M+34.2% | -$25.82M+31.0% | ||
| -3.5%+29.5pp | -5%+31.2pp | -11.9%+39.8pp | -21.2%+59.9pp | -33%+103pp | ||
| -$6.12M+76.7% | -$7.98M+67.3% | -$14.53M+42.3% | -$22.18M+33.4% | -$26.28M+30.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s revenue?
- Tarsus Pharmaceuticals, Inc. (TARS) generated $535.1M in revenue over the trailing twelve months, up 129.0% year over year.
- Is Tarsus Pharmaceuticals, Inc. profitable?
- Tarsus Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $48.3M over the trailing twelve months, a -9.0% net margin.
- What are Tarsus Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 42.7% and operating margin is -9.5%, with a -9.0% net margin.
- What is Tarsus Pharmaceuticals, Inc.'s earnings per share?
- Tarsus Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.13.
- Where does Tarsus Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
